{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.8","upperLimit":"44.4","value":"26.5"},{"groupId":"OG001","lowerLimit":"17.6","upperLimit":"42.9","value":"29.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Organ response was evaluated on the basis of improvement of one or more affected organ; only one parameter was required to satisfy the criteria. Response needed to be maintained for a minimum of 3 months to be considered valid.\n\nRenal response required a 50% reduction in 24-hour urine protein excretion (at least 0.5 g/d) with stable creatinine. Cardiac response required one of \\>= 2-mm reduction in the interventricular septal (IVS) thickness by echocardiogram, or improvement of ejection fraction by \\>= 20%, or improvement by 2 NYHA classes without an increase in diuretic use. Hepatic response required either \\>= 50% decrease in (or normalization of) an initially elevated alkaline phosphatase level or reduction in the size of the liver by at least 2 cm by radiographic determination. Gastrointestinal tract improvement was defined as normalization of a low serum carotene level, or reduction of diarrhea to \\< 50% of previous movements/day, or decrease in fecal fat excretion by 50%.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive low-dose melphalan 20 mg/m\\^2 IV over 15-30 minutes on day 1 or 0.12 mg/kg tablet orally once daily on days 1-7 and dexamethasone 40 mg orally on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses. (Study treatment beyond one year is not allowed.)","id":"OG000","title":"Low-Dose Melphalan"},{"description":"Patients receive filgrastim (G-CSF) 10 mg/kg/day on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan 140 mg/m\\^2 IV for low risk or 200 mg/m\\^2 IV for high risk patients over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.","id":"OG001","title":"High-Dose Melphalan + Autologous HSC"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"10 years","title":"Organ Response to Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}